Journal article
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
Annals of oncology, Vol.24(2), pp.441-448
02/2013
DOI: 10.1093/annonc/mds429
PMID: 23041589
Abstract
Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict survival. However, limited data exist regarding the role of FLIPI in the era of routine first-line rituximab (R) and R-chemotherapy regimens and in the setting of community oncology practices.
We evaluated the outcome data from the National LymphoCare Study (NLCS), a prospective, observational cohort study, which collects data on patients with FL in the United States (US) community practices.
Among 1068 male and 1124 female patients with FLIPI data, most were treated in US community practices (79%); 35% were FLIPI good risk, 30% intermediate risk, and 35% poor risk. FLIPI risk groups were significant predictors of overall survival (OS) and progression-free survival (PFS) for patients who undergo watchful waiting (WW), and those who receive non-R-containing regimens, R-alone, and R-chemotherapy combinations.
In the setting of contemporary practice with routine R use, stratifying patients into good, intermediate, and poor FLIPI risk groups predicts distinct outcomes in terms of OS and PFS. FLIPI remains an important prognostic index in the R era and should be used in clinical practices to support discussions about prognosis.
Details
- Title: Subtitle
- Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
- Creators
- A.K Nooka - Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, AtlantaB.K Link - Oncology and Bone & Marrow Transplantation, Division of Hematology, University of Iowa, Iowa CityJ.R Cerhan - Department of Health Sciences Research, Mayo Clinic-College of Medicine, RochesterC Nabhan - Division of Hematology/Oncology, Advocate Lutheran General Hospital and Oncology Specialists, Park RidgeX Zhou - RTI Health Solutions, Research Triangle ParkM.D Taylor - Genentech, South San FranciscoM Byrtek - Genentech, South San FranciscoT.P Miller - Section of Hematology/Oncology, University of Arizona, TucsonJ.W Friedberg - Department of Medicine, James P. Wilmont Cancer Center, RochesterA.D Zelenetz - Department of Medicine, Lymphoma Program, Memorial Sloan-Kettering Cancer Center, New YorkH Dillon - The Leukemia & Lymphoma Society, White Plains, USAR Sinha - Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, AtlantaP.J Shenoy - Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, AtlantaD Levy - Genentech, South San FranciscoK Dawson - Genentech, South San FranciscoJ.H Hirata - Genentech, South San FranciscoC.R Flowers - Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, Atlanta
- Resource Type
- Journal article
- Publication Details
- Annals of oncology, Vol.24(2), pp.441-448
- Publisher
- Elsevier Ltd
- DOI
- 10.1093/annonc/mds429
- PMID
- 23041589
- ISSN
- 0923-7534
- eISSN
- 1569-8041
- Language
- English
- Date published
- 02/2013
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984094562702771
Metrics
8 Record Views